Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROACTIVE study of pharmacokinetic boosting of olaparib
2024-516414-38-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of olaparib, ritonavir and cobicistat in cancer (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: AUC0-12h of regular versus boosted olaparib and Dose reductions due to toxicity. Planned start Oct 2024; status: authorised.
02
Drugs
olaparibritonavircobicistat
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-516414-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516414-38-00.